From: Advances in single-cell RNA sequencing and its applications in cancer research
Malignancies | Year | Species | Protocol | Accession number (custom database if available) | Clinical significance | References |
---|---|---|---|---|---|---|
Diffuse large B cell lymphoma | 2019 | Mouse | Smart-seq2 | Correspondence with authors | Identified a “superphagocytic” macrophage subset that expressed CD36/FCGR4, and defined a novel mechanism through which high-dose alkylating agents promote macrophage-dependent lymphoma clearance | [228] |
2020 | Human | 10 × Genomics | GEO: GSE139891 | Identified multiple functionally linked subpopulations. Effectively provided a single cell-COO for ∼80% of DLBCLs and identified novel prognostic subgroups of DLBCL | [213] | |
2022 | Mouse | GEXSCOPE® platform | Correspondence with authors | Combination treatment with dacinostat (LAQ824) and a c-Fos inhibitor more potently inhibited tumor cells both in vitro and in vivo | [264] | |
2022 | Human | 10 × Genomics | CNGBdb: CNP0001940 | TME cells may promote DLBCL activation/survival through CD40- and BAFF-mediated signals. Coinhibitory signals through TIM3 and TIGIT may drive T-cell exhaustion in DLBCL. HBV infection likely contributes to malignant cell survival/immune evasion in DLBCL | [216] | |
2022 | Human | 10 × Genomics | GEO: GSE182436 | Expression of both PD-1 and A2aR potentially defined a subset of much more dysfunctional CD8+ T cells and was associated with inferior outcomes | [265] | |
Follicular lymphoma | 2022 | Human | 10 × Genomics | EGA: EGAD00001008311 | Largely updated the NHC taxonomy in human LNs, performed an analysis of disease status, and provided a rich resource and deeper insights into LN and lymphoma biology to advance lymphoma management and therapy | [112] |
Mantle cell lymphoma | 2020 | Human | 10 × Genomics | Correspondence with authors | The drug resistance mechanisms of different cell clusters included drug metabolism, DNA damage repair, apoptosis, and survival promotion | [226] |
2021 | Human | 10 × Genomics | EGA: EGAS00001005019 | Due to the 17q gain, BIRC5/survivin expression was upregulated in resistant MCL tumor cells, and targeting BIRC5 resulted in marked tumor inhibition in preclinical models | [227] | |
B-cell lymphoma | 2022 | Human | 10 × Genomics | EGA: EGAS00001005356 | TIGIT blockade alone improved the antitumor function of CAR-T cells | [75] |
Burkitt lymphoma | 2022 | Mouse | 10 × Genomics | GEO: GSE190598 | Paclitaxel promoted the clearance of lymphoma by directly evoking the phagocytic capability of macrophages. Activation of Src family tyrosine kinase signaling in macrophages by paclitaxel promoted phagocytosis against NHL cells | [225] |
Peripheral T cell lymphoma | 2022 | Mouse | 10 × Genomics | GEO: GSE166673 | Vav1-Myo1f induces the development of GATA3+ Th2-like PTCL and accumulation of TAMs. TAMs can be targeted for the treatment of high-risk PTCL | [266] |
2022 | Cell line | 10 × Genomics | GEO: GSE204876 | PTCL had distinct DNMT3A mutation patterns and prognostic outcomes. DNMT3A mutations were associated with an activated, cytotoxic phenotype in the PTCL-TBX21 subtype | [230] | |
Angioimmunoblastic T cell lymphoma | 2022 | Human and mouse | 10 × Genomics | ENA: ERP138895 or EGA: EGAS00001006401 | Tet2-deficient immune cells functioned as a niche for AITL development. ACH-derived GCB cells potentially undergo independent clonal evolution and support tumorigenesis in AITL via the CD40-CD40LG axis | [134] |
Adult T cell leukemia-lymphoma | 2021 | Human | 10 × Genomics | NBDC: JGAS000301 | Identified possible molecular mechanisms of multistep tumorigenesis and revealed the transcriptomic changes in identical infected clones over time during multistep tumorigenesis | [267] |
2022 | Human | 10 × Genomics | GEO: GSE195674 | Identified a novel subset of CAFs, suggesting a potential target for targeted therapy to enhance treatment | [268] | |
Cutaneous T cell lymphoma | 2019 | Human | 10 × Genomics | Correspondence with authors | FOXP3 was identified as the most important factor to predict early disease in patients with CTCL. Transcriptome differences within a clonal tumor can be used to predict disease stage and thereby offer guidance for therapy | [73] |
2021 | Human | 10 × Genomics | GSE173205 | Identified a specific panel of biomarkers that might be used for monitoring MF disease progression | [217] | |
2022 | Human | 10 × Genomics | GSE124899 and GSE14658 | New cellular clusters after progression of the therapy notably exhibited increased expression of the transcriptional factor FOXP3, raising the potential implication of an evolving mechanism of immune evasion | [209] | |
2022 | Human | 10 × Genomics | GSE182861 | Provided unprecedented new insights into MF/SS pathogenesis by reporting the transcriptional profile of malignant T-cell clones in the skin and blood of individual patients | [269] | |
2022 | Human | 10 × Genomics | GSE197619 | Identified putative precancerous circulating clonal CD4+ T-cell populations in patients with CTCL. The therapeutic potential of targeting CD82 and JAK was reported | [130] | |
2022 | Human | 10 × Genomics | NCBI BioProject database PRJNA754592 | Provided the first comprehensive compendium of genomic alterations in tCTCL, and identified potential prognostic signatures and novel therapeutic targets for a case of incurable T-cell lymphoma | [131] | |
2022 | Human | 10 × Genomics | dbGaP: phs002933.v1.p1 | Supported further study of KIR3DL2 expression and CD8 immune populations as predictive biomarkers of pembrolizumab response in patients with Sézary syndrome | [224] | |
T-cell lymphoma | 2022 | Zebrafish | 10 × Genomics | GSE166646 | Described the oncogenicity of IRF4 in vivo, its potential effects on T-cell development, and clonal evolution using a zebrafish model. IRF4-driven tumors were sensitive to a BRD inhibitor | [270] |
Classic Hodgkin lymphoma | 2021 | Human | 10 × Genomics | EGA: EGAS00001005541 | This study strongly suggested the pathogenic importance of the CXCL13/CXCR5 axis and that PD-1+CXCL13+ T cells are a treatment target in LR-CHL | [271] |